[go: up one dir, main page]

CL2008000842A1 - Uso de una composicion que comprende un polipeptido de interleucina-18 (il-18) en combinacion con un vehiculo y un anticuerpo monoclonal contra un antigeno que se expresa en la superficie de una celula cancerosa que no sea un anticuerpo anti-cd20 par - Google Patents

Uso de una composicion que comprende un polipeptido de interleucina-18 (il-18) en combinacion con un vehiculo y un anticuerpo monoclonal contra un antigeno que se expresa en la superficie de una celula cancerosa que no sea un anticuerpo anti-cd20 par

Info

Publication number
CL2008000842A1
CL2008000842A1 CL200800842A CL2008000842A CL2008000842A1 CL 2008000842 A1 CL2008000842 A1 CL 2008000842A1 CL 200800842 A CL200800842 A CL 200800842A CL 2008000842 A CL2008000842 A CL 2008000842A CL 2008000842 A1 CL2008000842 A1 CL 2008000842A1
Authority
CL
Chile
Prior art keywords
cancerose
interleucin
polypeptide
cell
vehicle
Prior art date
Application number
CL200800842A
Other languages
English (en)
Inventor
Zdenka Jonak Zdenka Lu Haskova
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CL2008000842A1 publication Critical patent/CL2008000842A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200800842A 2007-03-23 2008-03-24 Uso de una composicion que comprende un polipeptido de interleucina-18 (il-18) en combinacion con un vehiculo y un anticuerpo monoclonal contra un antigeno que se expresa en la superficie de una celula cancerosa que no sea un anticuerpo anti-cd20 par CL2008000842A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
CL2008000842A1 true CL2008000842A1 (es) 2008-10-17

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
CL200800818A CL2008000818A1 (es) 2007-03-23 2008-03-20 Uso de polipeptido de il-18 humana y un anticuerpo anti-cd para tratar o prevenir cancer.
CL200800842A CL2008000842A1 (es) 2007-03-23 2008-03-24 Uso de una composicion que comprende un polipeptido de interleucina-18 (il-18) en combinacion con un vehiculo y un anticuerpo monoclonal contra un antigeno que se expresa en la superficie de una celula cancerosa que no sea un anticuerpo anti-cd20 par

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL200800818A CL2008000818A1 (es) 2007-03-23 2008-03-20 Uso de polipeptido de il-18 humana y un anticuerpo anti-cd para tratar o prevenir cancer.

Country Status (21)

Country Link
US (4) US20080274078A1 (es)
EP (3) EP2338514A1 (es)
JP (2) JP2010522200A (es)
KR (2) KR20100014530A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231114A1 (es)
BR (2) BRPI0808943A2 (es)
CA (2) CA2681851A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970885A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31265B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118733A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767207B2 (en) * 2000-02-10 2010-08-03 Abbott Laboratories Antibodies that bind IL-18 and methods of inhibiting IL-18 activity
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
TN2016000472A1 (en) 2014-04-25 2018-04-04 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
EP1292697B1 (en) 2000-06-15 2009-07-22 SmithKline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030202975A1 (en) * 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
CA2501757C (en) * 2002-10-08 2012-04-24 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
CA2502552C (en) * 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP4753867B2 (ja) * 2003-04-15 2011-08-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
WO2006111524A2 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
ES2530265T3 (es) * 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
CA2656836A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
WO2008033499A2 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
JP2010522239A (ja) 2010-07-01
EP2136841A2 (en) 2009-12-30
EP2338514A1 (en) 2011-06-29
AR065818A1 (es) 2009-07-01
MA31265B1 (fr) 2010-03-01
CR11075A (es) 2010-03-22
CA2681851A1 (en) 2008-10-02
JP2010522200A (ja) 2010-07-01
BRPI0809079A2 (pt) 2019-03-06
EP2129398A1 (en) 2009-12-09
EA200970884A1 (ru) 2010-04-30
US20100196310A1 (en) 2010-08-05
TW200904469A (en) 2009-02-01
MX2009010269A (es) 2009-10-12
PE20090190A1 (es) 2009-03-22
CL2008000818A1 (es) 2008-09-26
NZ579179A (en) 2011-12-22
MA31264B1 (fr) 2010-03-01
WO2008118733A3 (en) 2008-11-27
TW200906436A (en) 2009-02-16
KR20100014530A (ko) 2010-02-10
AU2008231025A1 (en) 2008-10-02
PE20090184A1 (es) 2009-03-22
AR065803A1 (es) 2009-07-01
MX2009010271A (es) 2009-10-12
US20100111945A1 (en) 2010-05-06
WO2008118736A1 (en) 2008-10-02
US20090035258A1 (en) 2009-02-05
AU2008231114A1 (en) 2008-10-02
US20080274078A1 (en) 2008-11-06
EA200970885A1 (ru) 2010-02-26
BRPI0808943A2 (pt) 2014-08-26
SG171674A1 (en) 2011-06-29
DOP2009000208A (es) 2010-03-31
IL200863A0 (en) 2010-05-17
WO2008118733A2 (en) 2008-10-02
KR20100015798A (ko) 2010-02-12
IL200525A0 (en) 2010-04-29
EP2136841A4 (en) 2010-07-07
CN101678102A (zh) 2010-03-24
CR10996A (es) 2009-11-12
CA2681827A1 (en) 2008-10-02
EP2129398A4 (en) 2010-04-21
DOP2009000220A (es) 2009-10-31

Similar Documents

Publication Publication Date Title
CL2008000842A1 (es) Uso de una composicion que comprende un polipeptido de interleucina-18 (il-18) en combinacion con un vehiculo y un anticuerpo monoclonal contra un antigeno que se expresa en la superficie de una celula cancerosa que no sea un anticuerpo anti-cd20 par
BRPI0820452A2 (pt) Anticorpos que reconhecendo um epítopo contendo um carboidrato em cd-43 e cea expressos em células cancerosas e métodos de uso dos mesmos.
AR074816A1 (es) Anticuerpo anti- idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloide
WO2012174367A3 (en) Device with inverted large scale light extraction structures
CA117983S (en) Bench seat
SG10201400426XA (en) Antibodies to ox-2/cd200 and uses thereof
AU306113S (en) Storage closure
CL2011000711A1 (es) Anticuerpo monoclonal que se une al receptor de regulacion negativa (nrr) de notch2; formulacion farmaceutica que lo comprende; y su uso para tratar una enfermedad maligna por celula b o melanoma.
EP2022662A4 (en) Power output device and vehicle with the same
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
IL226343A0 (en) Monoclonal antibodies against a rgm protein and their uses
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0712259B8 (pt) construção adesiva em camadas útil para fixar uma bolsa de coleta ou um dispositivo de coleta à área perianal
CL2008002613A1 (es) Uso de una combinacion de un anticuerpo anti-cd20 de tipo i con un anticuerpo anti-cd20 de tipo ii para tratar cancer que expresa cd20.
EP2535941A3 (en) Photovoltaic Device with Reflection Enhancing Layer
CL2008000493A1 (es) Polipeptido que se une especificamente a un dominio pdz de la proteina htra1; polinucleotido que lo codifica; metodo de produccion; anticuerpo que se une a el; y su uso para tratar patologias relacionadas con la proteina htra1.
BR112012019475A2 (pt) "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
BRPI0817463A2 (pt) Composição de combustível diesel, pacote aditivo e uso de um aditivo em uma composição de combustível diesel.
MX2012001148A (es) Compuesto de pelicula de espejo solar que tiene alta resitencia a la intemperie y estabilidad a los rayos ultravioleta.
BR112012012369A2 (pt) artigo abrasivo e método para a formação de um artigo abrasivo
WO2008063982A3 (en) High mannose glycoprotein epitopes
FR2936218B1 (fr) Structure primaire pour aeronef en materiau composite a tenue au crash amelioree et element structural absorbeur d'energie associe.
FR2910859B1 (fr) Dispositif de rangement de bagages pour vehicule de transport en commun
BRPI0722305A2 (pt) Navio para assentar uma tubulação, método de assentar uma tubulação com um navio, e, uso do navio
EP2781823A3 (en) Light-emitting body and manufacturing method thereof, and light-emitting device including the same